MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Hutchison China MediTech Ltd ADR

Geschlossen

BrancheGesundheitswesen

16.54 2.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.96

Max

16.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

6M

Verkäufe

162M

KGV

Branchendurchschnitt

77.1

39.564

Gewinnspanne

3.676

Angestellte

1,811

EBITDA

-5M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+28.47% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.7B

Vorheriger Eröffnungskurs

13.93

Vorheriger Schlusskurs

16.54

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Juli 2025, 22:07 UTC

Wichtige Markttreiber

Trade Desk Rises on S&P 500 Inclusion

14. Juli 2025, 17:06 UTC

Wichtige Markttreiber

Crypto Assets Rally Ahead of Possible U.S. Legislation

14. Juli 2025, 16:47 UTC

Akquisitionen, Fusionen, Übernahmen

NatWest to Sell Stake in Permanent TSB

14. Juli 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14. Juli 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14. Juli 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14. Juli 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14. Juli 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14. Juli 2025, 23:01 UTC

Ergebnisse

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14. Juli 2025, 23:01 UTC

Ergebnisse

China Vanke Expects 1H Loss to Widen >000002.SZ

14. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. Juli 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14. Juli 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14. Juli 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14. Juli 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14. Juli 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14. Juli 2025, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14. Juli 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14. Juli 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Juli 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14. Juli 2025, 16:53 UTC

Heiße Aktien

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14. Juli 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

14. Juli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Juli 2025, 16:12 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer-Vergleich

Kursveränderung

Hutchison China MediTech Ltd ADR Prognose

Kursziel

By TipRanks

28.47% Vorteil

12-Monats-Prognose

Durchschnitt 20.85 USD  28.47%

Hoch 27 USD

Tief 14.7 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hutchison China MediTech Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

14.24 / 14.78Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.